Vivanza Biosciences Share Price
1.74+0.00 (+0.00%)
-15.94% past 1 Year
Vivanza Biosciences Ltd was Incrporated in the year of 1982. The company is in the business activity of Trading Of Pharmaceutical Products. The company's range of products and services include
Corporate filings & documents
Announcements
Please find enclosed newspaper advertisement w.r.t Notice of 44th AGM of the Company and e-voting information.
2 weeks agoPlease find enclosed newspaper advertisement w.r.t Notice of 44th AGM of the Company and e-voting information.
2 weeks agoAnnual Report for the Financial Year 2025-2026 of the Company.
2 weeks agoAnnual Report for the Financial Year 2025-2026 of the Company.
2 weeks agoNotice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26
2 weeks agoNotice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26
2 weeks agoThe Board of Directors of the Company at its meeting held on Monday August 17 2026 at the Registered Office inter alia considered and approved: 1. Directors Report Secretarial Audit Report and annexures for FY 2025-26; 2. Convening of the 44th AGM and draft Notice thereof; 3. Appointment of Mr. Chintan K. Patel PCS (Mem. No. A31987 COP No. 11959) as Scrutinizer; 4. September 04 2026 as the cut-off date for AGM voting eligibility; 5. Adoption of new MoA and AoA subject to Members approval; 6. Seeking Members approval for material Related Party Transactions for FY 2026-27; 7. Enhancement of borrowing limits under Section 180(1)(c); 8. Financial transactions involving loans guarantees or securities under Section 185; and 9. Investments loans guarantees or securities beyond prescribed limits under Section 186 of the Companies Act 2013.
2 weeks agoThe Board of Directors of the Company at its meeting held on Monday August 17 2026 at the Registered Office inter alia considered and approved: 1. Directors Report Secretarial Audit Report and annexures for FY 2025-26; 2. Convening of the 44th AGM and draft Notice thereof; 3. Appointment of Mr. Chintan K. Patel PCS (Mem. No. A31987 COP No. 11959) as Scrutinizer; 4. September 04 2026 as the cut-off date for AGM voting eligibility; 5. Adoption of new MoA and AoA subject to Members approval; 6. Seeking Members approval for material Related Party Transactions for FY 2026-27; 7. Enhancement of borrowing limits under Section 180(1)(c); 8. Financial transactions involving loans guarantees or securities under Section 185; and 9. Investments loans guarantees or securities beyond prescribed limits under Section 186 of the Companies Act 2013.
2 weeks agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 inter alia to consider and approve 1) To consider and approve the Directors Report and Secretarial Audit Report along with annexure for the Financial Year 2025-26;2) To consider and approve the convening of the 44th (AGM) of the Members of the Company and to approve the draft Notice of the 44th AGM of the Company;3) To appoint Mr. Chintan K. Patel Practicing Company Secretary (Mem No: A31987 COP: 11959) as Scrutinizer for the the 44th AGM;4) Fixing of September 04 2026 as the "Cut-Off Date" for 44th Annual General Meeting of the Company.5) To consider and approve the proposal for adoption of the Memorandum of Association and Articles of Association of the Company in conformity with the provisions of the Companies Act 2013 and to recommend the same for approval of the Members at the ensuing Annual General Meeting.6. To consider and approve the proposal for obtaining approval of the Members for the proposed transaction under Section 180(1)(c) 185 and 186 of the Companies Act 20137. any other business
3 weeks agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 inter alia to consider and approve 1) To consider and approve the Directors Report and Secretarial Audit Report along with annexure for the Financial Year 2025-26;2) To consider and approve the convening of the 44th (AGM) of the Members of the Company and to approve the draft Notice of the 44th AGM of the Company;3) To appoint Mr. Chintan K. Patel Practicing Company Secretary (Mem No: A31987 COP: 11959) as Scrutinizer for the the 44th AGM;4) Fixing of September 04 2026 as the "Cut-Off Date" for 44th Annual General Meeting of the Company.5) To consider and approve the proposal for adoption of the Memorandum of Association and Articles of Association of the Company in conformity with the provisions of the Companies Act 2013 and to recommend the same for approval of the Members at the ensuing Annual General Meeting.6. To consider and approve the proposal for obtaining approval of the Members for the proposed transaction under Section 180(1)(c) 185 and 186 of the Companies Act 20137. any other business
3 weeks agoPursuant to Regulation 32 of the SEBI(LODR) Regulation 2015 Read with SEBI circular dated 24th December 2019 regarding the submission of the statement of deviation or variation from the proceeds of public issue/rights issue/preferential issue qualified institutional placement etc. we hereby confirm that the company has not raised any further funds by means of Public Issue rights issue or preferential issue etc. hence the statement of deviation and variation is not applicable to the company.
3 weeks agoPursuant to Regulation 32 of the SEBI(LODR) Regulation 2015 Read with SEBI circular dated 24th December 2019 regarding the submission of the statement of deviation or variation from the proceeds of public issue/rights issue/preferential issue qualified institutional placement etc. we hereby confirm that the company has not raised any further funds by means of Public Issue rights issue or preferential issue etc. hence the statement of deviation and variation is not applicable to the company.
3 weeks agoin the terms of Regulation 47 of the SEBI(LODR) Regulation 2015 Please find the copy of the Newspaper in the English and vernacular Language of the State wherein the Unaudited Standalone and Consolidated Financial Statements for the Quarter Ended on June 30 2026 Published.
3 weeks agoin the terms of Regulation 47 of the SEBI(LODR) Regulation 2015 Please find the copy of the Newspaper in the English and vernacular Language of the State wherein the Unaudited Standalone and Consolidated Financial Statements for the Quarter Ended on June 30 2026 Published.
3 weeks agoApproval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and other items .
4 weeks agoApproval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and other items .
4 weeks agoApproval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and other items .
4 weeks agoApproval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and other items .
4 weeks agoApproved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June 2026 along with year-to-date figures for the period from 1st April 2026 to 30th June 2026 together with the Limited Review Report (Annexure -A). and Other Business of the Company as enclosed.
4 weeks agoApproved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June 2026 along with year-to-date figures for the period from 1st April 2026 to 30th June 2026 together with the Limited Review Report (Annexure -A). and Other Business of the Company as enclosed.
4 weeks agoThe Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026 The Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026
1 month agoThe Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026 The Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026
1 month agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 inter alia to consider and approve 1. Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter ended on June 30 20262. Take note of the Notice of Disclosure of Interest and Intimation u/s 164 of the Companies Act 20133. Take note of Declarations from Independent Directors U/S 149(7) of The Companies Act 20134. Any other business with the permission of the chair
1 month agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 inter alia to consider and approve 1. Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter ended on June 30 20262. Take note of the Notice of Disclosure of Interest and Intimation u/s 164 of the Companies Act 20133. Take note of Declarations from Independent Directors U/S 149(7) of The Companies Act 20134. Any other business with the permission of the chair
1 month agowe hereby declared that statutory auditor of the company M/s Shivam Soni & co Chartered Accountant (FRN: 152477W) have issued an Audit Report with unmodified opinion on the Audited Financial Result of the Company for the Quarter and year ended on 31st March 2026.
1 month agowe hereby declared that statutory auditor of the company M/s Shivam Soni & co Chartered Accountant (FRN: 152477W) have issued an Audit Report with unmodified opinion on the Audited Financial Result of the Company for the Quarter and year ended on 31st March 2026.
1 month agopursuant to regulation 30 of the SEBI(LODR) Regulations 2015 appointmnet of Mr. Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer has been approved with effect from 09th July 2026
1 month agopursuant to regulation 30 of the SEBI(LODR) Regulations 2015 appointmnet of Mr. Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer has been approved with effect from 09th July 2026
1 month agoPursuant to Regulation 29 and other applicable provisions of the SEBI (LODR) Regulations 2015 this is to inform you that a meeting of the Board of Directors of the Company was held on Thursday 09th July 2026 to transact the following business: considered and approved 1. the transfer of unverified shares to their rightful owner 2. Appointment of Mr Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer 3. took note of DPT-3 for the financial year 2025-2026 and agreement which provides for strategic cooperation for the establishment of a Plastic Film Manufacturing Project in the Kyrgyz Republic.
1 month agoPursuant to Regulation 29 and other applicable provisions of the SEBI (LODR) Regulations 2015 this is to inform you that a meeting of the Board of Directors of the Company was held on Thursday 09th July 2026 to transact the following business: considered and approved 1. the transfer of unverified shares to their rightful owner 2. Appointment of Mr Vishal Sureshbhai Katarmal as a Company Secretary and Compliance Officer 3. took note of DPT-3 for the financial year 2025-2026 and agreement which provides for strategic cooperation for the establishment of a Plastic Film Manufacturing Project in the Kyrgyz Republic.
1 month agoCertificate under Regulation 47(5) of the SEBI ( Depository and Participant) Regulations 2018 received from Purva Share Registry (I) Pvt Ltd and the share transfer agent (RTA) of the Company for the Quarter ended on 30th June 2026.
1 month agoCertificate under Regulation 47(5) of the SEBI ( Depository and Participant) Regulations 2018 received from Purva Share Registry (I) Pvt Ltd and the share transfer agent (RTA) of the Company for the Quarter ended on 30th June 2026.
1 month agoIntimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015- Execution of Strategic Corporation Investment & Technology Transfer Agreement
2 months agoIntimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015- Execution of Strategic Corporation Investment & Technology Transfer Agreement
2 months agoIntimation of Closure of Trading Window for the Quarter ended on 30th June 2026
2 months agoIntimation of Closure of Trading Window for the Quarter ended on 30th June 2026
2 months agoPursuant to Reg 29 and other applicable provisions of SEBI LODR Reg 2015 this is to inform you that a meeting of the Board of Directors of the Company held on 18th June 2026 has considered and transacted the attached businesses for the change of management related.1. Appointment of the Internal Auditor M/s. Dharti Shah & Co. and Appointment of Mr. Hemant Amrish Parikh (DIN: 00027820) as an additional non-executive non-independent director.
2 months agoPursuant to Reg 29 and other applicable provisions of SEBI LODR Reg 2015 this is to inform you that a meeting of the Board of Directors of the Company held on 18th June 2026 has considered and transacted the attached businesses for the change of management related.1. Appointment of the Internal Auditor M/s. Dharti Shah & Co. and Appointment of Mr. Hemant Amrish Parikh (DIN: 00027820) as an additional non-executive non-independent director.
2 months ago1.The Board of Directors of the Company at its meeting held today has considered and approved the following transactions. The meeting of the Board of Directors of the Company commenced at 13:30 P.M. and concluded at 14:00 P.M.
2 months ago1.The Board of Directors of the Company at its meeting held today has considered and approved the following transactions. The meeting of the Board of Directors of the Company commenced at 13:30 P.M. and concluded at 14:00 P.M.
2 months agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 inter alia to consider and approve 1.To authorise Mr. Sarang Bharatbhai Pathak (DIN: 02663344) to sign the Financial Statements for the financial year ended 31st March 2026 on behalf of the Board 2.To take note of the consent received from M/s. Dharti Shah & Co. and appoint it as an Internal Auditor of the Company for the Financial Year 2026-2027. 3.To consider and approve the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director of the Company. 4. To consider and approve the transfer of certain unverified shares to the Unclaimed Suspense Account pending verification of the identity and entitlement of the rightful shareholders and to authorize the Registrar and Share Transfer Agent to process and release such shares from the Unclaimed Suspense Account upon receipt and verification of the prescribed KYC and other supporting documents subject to confirmation by the Company and applicable laws.
2 months agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 inter alia to consider and approve 1.To authorise Mr. Sarang Bharatbhai Pathak (DIN: 02663344) to sign the Financial Statements for the financial year ended 31st March 2026 on behalf of the Board 2.To take note of the consent received from M/s. Dharti Shah & Co. and appoint it as an Internal Auditor of the Company for the Financial Year 2026-2027. 3.To consider and approve the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director of the Company. 4. To consider and approve the transfer of certain unverified shares to the Unclaimed Suspense Account pending verification of the identity and entitlement of the rightful shareholders and to authorize the Registrar and Share Transfer Agent to process and release such shares from the Unclaimed Suspense Account upon receipt and verification of the prescribed KYC and other supporting documents subject to confirmation by the Company and applicable laws.
2 months agoIn terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st 2026
3 months agoIn terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st 2026
3 months agoThis is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations 2015 Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations 2015 shall not apply to listed entities having paid up equity share capital not exceeding Rupees 10 crores and net worth not exceeding Rupees 25 crores as on the last day of previous financial year. The paid-up equity share capital and net worth of the Company as on 31st March 2025 are Rs. 4 00 00 000 and Rs. 4 02 03 752.40 respectively
3 months agoAudited Standalone Financial Results for the Quarter and Year ended on 31st March 2026 Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS Reconstitution of Committees of the Board
3 months agoConsideration of Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Audit Report of the Company for the Quarter and Year ended 31st March 2026 Took note of the Resignation of Mr. Hemant Amrish Parikh as a Non-Executive Director of the Company Took note of the Resignation of CS Chaitra Arora from the position of the CS and compliance officer Reconstitution of Committees of the Board with effect from 07th May 2026
3 months agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 inter alia to consider and approve This is in continuation of our earlier intimation dated April 28 2026 regarding the Board Meeting scheduled on May 4 2026 to consider and approve the audited standalone and consolidated financial results along with the Audit Report for the quarter and year ended March 31 2026.Due to unavoidable circumstances the meeting has been rescheduled to May 7 2026 to consider the same agenda.Further the trading window shall remain closed until 48 hours after the declaration of the said financial results in accordance with the Companys Code of Conduct for Prevention of Insider Trading.
4 months agoVivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 inter alia to consider and approve This is in continuation of our earlier intimation dated April 28 2026 regarding the Board Meeting scheduled on May 4 2026 to consider and approve the audited standalone and consolidated financial results along with the Audit Report for the quarter and year ended March 31 2026.Due to unavoidable circumstances the meeting has been rescheduled to May 7 2026 to consider the same agenda.Further the trading window shall remain closed until 48 hours after the declaration of the said financial results in accordance with the Companys Code of Conduct for Prevention of Insider Trading.
4 months agoIntimation Regarding Resignation of Company Secretary & Compliance Officer pursuant to Regulation 30 of SEBI(LODR) Regulations 2015.
4 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2023-03-24
Split
10:1
Company details
Registered office
403 Sarthik 2 Opp. Rajpath Club S. G Highway, Bodakdev Ahmedabad Gujarat PIN: 380054 Tel No: 079 26870953 Fax No: NULL Email: [email protected] Internet: www.vivanzabiosciences.com
Registrars
PIN: Tel No: Fax No: Email:
Management
Jayendra Mehta, Managing Director
Sarang Pathak, Non Independent & Non Executive Director
HA Parikh, Non Independent & Non Executive Director
Rina Kumari, Non Executive Independent Director
Hitesh Rijwani, Non Executive Independent Director
Vishal Katarmal, Company Secretary & Compliance Officer
Details
BSE 530057
NSE NULL
ISIN INE984E01035